Cargando…
Protocol for evaluating antitumor activity of KIR3DL3 blockade in an NK cell-based xenogeneic lung tumor model
Human killer cell immunoglobulin-like receptor, three Ig domains and long cytoplasmic tail (KIR3DL3) is expressed on natural killer (NK) cells and is a newly identified inhibitory receptor for B7 family member HERV-H LTR-associating protein 2 (HHLA2). Here, we summarize the isolation and expansion o...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9641272/ https://www.ncbi.nlm.nih.gov/pubmed/36386885 http://dx.doi.org/10.1016/j.xpro.2022.101818 |
_version_ | 1784826061766262784 |
---|---|
author | Ren, Xiaoxin Corrigan, Devin T. Zang, Xingxing |
author_facet | Ren, Xiaoxin Corrigan, Devin T. Zang, Xingxing |
author_sort | Ren, Xiaoxin |
collection | PubMed |
description | Human killer cell immunoglobulin-like receptor, three Ig domains and long cytoplasmic tail (KIR3DL3) is expressed on natural killer (NK) cells and is a newly identified inhibitory receptor for B7 family member HERV-H LTR-associating protein 2 (HHLA2). Here, we summarize the isolation and expansion of KIR3DL3(+) human NK cells, and in vitro functional characterization of in-house anti-KIR3DL3 monoclonal antibody (mAb). We also describe a human NK cell-based xenogeneic lung tumor model for testing the therapeutic activity of KIR3DL3 blockade in vivo. For complete details on the use and execution of this protocol, please refer to Wei et al. (2021). |
format | Online Article Text |
id | pubmed-9641272 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-96412722022-11-15 Protocol for evaluating antitumor activity of KIR3DL3 blockade in an NK cell-based xenogeneic lung tumor model Ren, Xiaoxin Corrigan, Devin T. Zang, Xingxing STAR Protoc Protocol Human killer cell immunoglobulin-like receptor, three Ig domains and long cytoplasmic tail (KIR3DL3) is expressed on natural killer (NK) cells and is a newly identified inhibitory receptor for B7 family member HERV-H LTR-associating protein 2 (HHLA2). Here, we summarize the isolation and expansion of KIR3DL3(+) human NK cells, and in vitro functional characterization of in-house anti-KIR3DL3 monoclonal antibody (mAb). We also describe a human NK cell-based xenogeneic lung tumor model for testing the therapeutic activity of KIR3DL3 blockade in vivo. For complete details on the use and execution of this protocol, please refer to Wei et al. (2021). Elsevier 2022-11-04 /pmc/articles/PMC9641272/ /pubmed/36386885 http://dx.doi.org/10.1016/j.xpro.2022.101818 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Protocol Ren, Xiaoxin Corrigan, Devin T. Zang, Xingxing Protocol for evaluating antitumor activity of KIR3DL3 blockade in an NK cell-based xenogeneic lung tumor model |
title | Protocol for evaluating antitumor activity of KIR3DL3 blockade in an NK cell-based xenogeneic lung tumor model |
title_full | Protocol for evaluating antitumor activity of KIR3DL3 blockade in an NK cell-based xenogeneic lung tumor model |
title_fullStr | Protocol for evaluating antitumor activity of KIR3DL3 blockade in an NK cell-based xenogeneic lung tumor model |
title_full_unstemmed | Protocol for evaluating antitumor activity of KIR3DL3 blockade in an NK cell-based xenogeneic lung tumor model |
title_short | Protocol for evaluating antitumor activity of KIR3DL3 blockade in an NK cell-based xenogeneic lung tumor model |
title_sort | protocol for evaluating antitumor activity of kir3dl3 blockade in an nk cell-based xenogeneic lung tumor model |
topic | Protocol |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9641272/ https://www.ncbi.nlm.nih.gov/pubmed/36386885 http://dx.doi.org/10.1016/j.xpro.2022.101818 |
work_keys_str_mv | AT renxiaoxin protocolforevaluatingantitumoractivityofkir3dl3blockadeinannkcellbasedxenogeneiclungtumormodel AT corrigandevint protocolforevaluatingantitumoractivityofkir3dl3blockadeinannkcellbasedxenogeneiclungtumormodel AT zangxingxing protocolforevaluatingantitumoractivityofkir3dl3blockadeinannkcellbasedxenogeneiclungtumormodel |